The Trump administration announced 100% tariffs on branded drug imports starting October 1, 2025. While exemptions exist for generics, European exports, and companies investing in US manufacturing, many small and mid-size biotech firms face significant exposure. The tariffs cast uncertainty over ongoing pharmaceutical negotiations and could disrupt supply chains, with potential knock-on effects on drug pricing strategies and access. Industry watchers await clarifications on enforcement and exemption criteria.